Develops precision cancer therapies for patients with cancers driven by the RAS/MAPK pathway, including RAS-targeting drugs and an EGFR antibody.
10-K for FY2025, filed Mar 12, 2026
Its intended customers are patients with RAS/MAPK pathway-driven cancers; the company is developing drug candidates and has not yet begun product sales.
10-K for FY2025, filed Mar 12, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$51.3MView ↗
8-K, filed Aug 24, 2026
On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track…View ↗
8-K, filed Jul 13, 2026
On July 13, 2026, Erasca, Inc. (the “Company”) announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS…View ↗
8-K, filed Apr 27, 2026
On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”). In the letter RevMed alleged…View ↗
Portfolio focus
The older report described candidates against several cancer cell signals, while the latest centers its clinical work on medicines targeting RAS and KRAS, retains an EGFR antibody in discovery, and says it stopped developing naporafenib.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 12, 2026Our modality-agnostic approach aims to allow us to selectively and potently inhibit or degrade critical signaling nodes with small molecule…View ↗
Target upstream and downstream MAPK pathway nodes with single agents and combinations intended to clamp these oncogenic drivers. Our lead…View ↗
Target RAS, the midstream MAPK pathway node, directly with single agents and combinations. We are discovering and developing molecules that…View ↗
Competes with Adlai Nortye, Amgen, Boehringer Ingelheim, BridgeBio Oncology Therapeutics, Bristol Myers Squibb, Eli Lilly, GenFleet Therapeutics, Jacobio Pharmaceuticals, Merck, Pfizer, Revolution Medicines, and Roche/Genentech
10-K for FY2025, filed Mar 12, 2026There are numerous companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology…View ↗
Loading...